For patients with MM who received pembrolizumab, patients with a BRAF V600E/K-mutation had a lower ORR as compared with patients with BRAF wild-type, but did not present a significant difference (34.3% vs. 39.8%) (104). This evidence concerns the gene BRAF and Miyoshi myopathy.